Enzo Biochem Inc Revenue Growth Rates (ENZ), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Enzo Biochem Inc  (NYSE: ENZ)
 

ENZ's Revenue Growth by Quarter and Year

Enzo Biochem Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENZ Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter July -
3rd Quarter April 6.40
2nd Quarter January 7.33
1st Quarter October 6.21
FY 19.94

ENZs Annual Revenue
Enzo Biochem Inc's Revenue in the fiscal year 2024 $ 31.91 millions
Enzo Biochem Inc's Revenue in the fiscal year 2023 $ 31.06 millions
Enzo Biochem Inc's Revenue in the fiscal year 2022 $ 107.07 millions
Enzo Biochem Inc's Revenue in the fiscal year 2021 $ 117.73 millions
Enzo Biochem Inc's Revenue in the fiscal year 2020 $ 76.02 millions




ENZ Revenue third quarter 2024 Y/Y Growth Comment
Enzo Biochem Inc reported decline in Revenue in the third quarter 2024 by -20.17% to $ 6.40 millions, from the same quarter in 2023.
The contraction in the third quarter 2024 Enzo Biochem Inc's Revenue compares unfavorably to the Company's average Revenue decrease of -3%.

Looking into third quarter 2024 results within Biotechnology & Pharmaceuticals industry 58 other companies have achieved higher Revenue growth. While Enzo Biochem Inc' s Revenue fall of -20.17% ranks overall at the positon no. 3655 in the third quarter 2024.


ENZ Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter July - - - -18.26 %
3rd Quarter April -20.17 % 7.08 % -71.43 % -20.06 %
2nd Quarter January -14.27 % 13.85 % -77.94 % 8.2 %
1st Quarter October -20.49 % 10 % -73.23 % -7.47 %
FY   - 1207.79 % -97.72 % -

Financial Statements
Enzo Biochem Inc's third quarter 2024 Revenue $ 6.40 millions ENZ's Income Statement
Enzo Biochem Inc's third quarter 2023 Revenue $ 8.02 millions Quarterly ENZ's Income Statement


ENZ Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter July - -6.11 % - -22.65 %
3rd Quarter April -12.66 % -6.2 % -0.27 % -23 %
2nd Quarter January 18.04 % 9.48 % 5.77 % 28.39 %
1st Quarter October -17.53 % - -64.99 % 6.89 %
FY (Year on Year)   - 1207.79 % -97.72 % -


Back to ENZ Growth rate Comparisons >> Back to ENZ Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #59
Healthcare Sector #535
Overall #3655

Revenue Y/Y Growth Statistics
High Average Low
94.03 % -3 % -77.93 %
(Oct 31 2020)   (Jul 31 2023)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #59
Healthcare Sector #535
Overall #3655
Revenue Y/Y Growth Statistics
High Average Low
94.03 % -3 % -77.93 %
(Oct 31 2020)   (Jul 31 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Enzo Biochem Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
46.75 % -2.29 % -100 %
(Oct 31 2020)  


ENZ's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Enzo Biochem Inc disclosed drop in Revenue from the second quarter by -12.66% to $ 6.40 millions, from $ 7.33 millions achived in the previous reporting period.

But that's not important problem, as Enzo Biochem Inc's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 55 other companies have achieved higher Revenue quarter on quarter growth. While Enzo Biochem Inc's Revenue growth quarter on quarter, overall rank is 3661.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #56
Healthcare Sector #543
Overall #3661
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #56
Healthcare Sector #543
Overall #3661
Revenue Q/Q Growth Statistics
High Average Low
46.75 % -2.29 % -100 %
(Oct 31 2020)  


ENZ's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Enzo Biochem Inc disclosed drop in Revenue from the second quarter by -12.66% to $ 6.40 millions, from $ 7.33 millions achived in the previous reporting period.

But that's not important problem, as Enzo Biochem Inc's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 55 other companies have achieved higher Revenue quarter on quarter growth. While Enzo Biochem Inc's Revenue growth quarter on quarter, overall rank is 3661.


Enzo Biochem Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Apr 30 2025)		 12 Months Ending
(Jan 31 2025)		 12 Months Ending
(Oct 31 2024)		 12 Months Ending
(Jul 31 2024)		 12 Months Ending
(Apr 30 2024)
Cumulative Revenue 12 Months Ending $ 27.48 $ 29.10 $ 30.31 $ 31.91 $ 4.72
Y / Y Revenue Growth (TTM) 481.97 % 595.39 % 863.88 % 1206.59 % -88.86 %
Year on Year Revenue Growth Overall Ranking # 3930 # 0 # 3354 # 3111 # 2990
Seqeuential Revenue Change (TTM) -5.57 % -4.02 % -4.99 % 575.85 % 12.83 %
Seq. Revenue Growth (TTM) Overall Ranking # 2582 # 0 # 2811 # 2850 # 2702


Cumulative Revenue growth Comment
With 481.97% annual Revenue growth, Enzo Biochem Inc would report a record annual Revenue surge if the fiscal year would end on Apr 30 2025.

In the Healthcare sector 569 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3930.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 570
Overall # 3930

Revenue TTM Y/Y Growth Statistics
High Average Low
481.97 %
 5.44 %
-93.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 42
Sector # 402
S&P 500 # 2582
Cumulative Revenue growth Comment
With 481.97% annual Revenue growth, Enzo Biochem Inc would report a record annual Revenue surge if the fiscal year would end on Apr 30 2025.

In the Healthcare sector 569 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3930.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 570
Overall # 3930

Revenue TTM Y/Y Growth Statistics
High Average Low
481.97 %
5.44 %
-93.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 42
Sector # 402
S&P 500 # 2582




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENZ's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Apr 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Apr 30 2025
Champions Oncology Inc -11.76%$ -11.763 millions
Enzo Biochem Inc-20.19%$ -20.194 millions


About Enzo Biochem Inc Revenue Growth Rates (ENZ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Enzo Biochem Inc (CIK 316253).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-25-054828
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Enzo Biochem Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.